Elios Financial Group Inc. Acquires New Holdings in Johnson & Johnson (NYSE:JNJ)

Elios Financial Group Inc. bought a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,422 shares of the company's stock, valued at approximately $717,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. International Assets Investment Management LLC lifted its holdings in shares of Johnson & Johnson by 20,130.0% in the third quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company's stock valued at $559,832,000 after purchasing an additional 3,437,397 shares in the last quarter. Marshall Wace LLP lifted its stake in Johnson & Johnson by 506.9% in the 2nd quarter. Marshall Wace LLP now owns 3,884,962 shares of the company's stock valued at $567,826,000 after buying an additional 3,244,862 shares in the last quarter. Ninety One UK Ltd increased its position in Johnson & Johnson by 59.0% during the second quarter. Ninety One UK Ltd now owns 6,708,943 shares of the company's stock worth $980,579,000 after buying an additional 2,489,925 shares in the last quarter. Swedbank AB acquired a new position in shares of Johnson & Johnson in the first quarter worth $331,178,000. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Johnson & Johnson by 10.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 18,780,645 shares of the company's stock valued at $2,744,979,000 after acquiring an additional 1,831,751 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

JNJ has been the subject of several analyst reports. Citigroup boosted their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a "buy" rating in a research note on Wednesday, October 16th. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, September 14th. Cantor Fitzgerald restated an "overweight" rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Morgan Stanley boosted their price target on Johnson & Johnson from $169.00 to $175.00 and gave the company an "equal weight" rating in a report on Wednesday, October 16th. Finally, Royal Bank of Canada lifted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a research report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $175.94.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of the company's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 22.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Down 0.2 %

NYSE JNJ traded down $0.37 during mid-day trading on Tuesday, hitting $154.17. The company's stock had a trading volume of 3,374,883 shares, compared to its average volume of 7,058,864. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The stock's fifty day simple moving average is $159.98 and its two-hundred day simple moving average is $156.36. The firm has a market capitalization of $371.18 billion, a P/E ratio of 22.21, a price-to-earnings-growth ratio of 2.76 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same quarter in the previous year, the business posted $2.66 EPS. The business's quarterly revenue was up 5.2% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.22%. Johnson & Johnson's payout ratio is currently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.